Revolutionising heart health: Frontier X Plus gains FDA clearance

[ad_1]

AW promotion: latest news about the market leader when it comes to monitoring your heart

Fourth Frontier, a medical technology company based out of New York and Bangalore, announced the 510(k) clearance of the Frontier X Plus from the U.S. FDA.

The Frontier X Plus is an innovative single-lead, continuous ECG monitor that is worn around the chest and wirelessly relays the user’s ECG instantly to remote dashboards. A range of advanced algorithms identify and classify cardiac rhythm as Bradycardia, Tachycardia, Normal Sinus Rhythm, or Atrial Fibrillation.

The device demonstrated best-in-class signal quality during a range of motions including during intense exercise. The wearable ECG monitor further demonstrated equivalence in the classification of cardiac arrhythmias when compared with the conventional 12-lead ECG, through clinical trials in India and the US.

According to the Center for Disease Control, one person dies every 33 seconds from Cardiovascular Disease (CVD), and CVDs are responsible for one in every five deaths in the US. The American Heart Association reports that between three to six million Americans have reported an incidence of Atrial Fibrillation. This number is expected to rise to 16 million by 2050.

Atrial Fibrillation has been described as a global epidemic and is a key indicator of reduced morbidity and mortality in individuals of all age groups. Globally, the incidence and prevalence of Cardiovascular Disease (CVD) has been increasingly observed in younger individuals and is one of the leading reasons for premature death.

“We have seen cardiac arrhythmias develop in individuals of all ages, and the incidence is significantly higher for individuals who are both active and have cardiac health risk factors,” said Manav Bhushan, co-founder and CEO of Fourth Frontier. “The percentage of population that falls in the confluence of these categories is continuously rising. Since the FX+ is able to capture ECGs during all kinds of motion and activity, we think this will be a game changer and significantly improve on the early detection of cardiovascular disease.”

With this clearance, the company plans to enter the US market as a prescription based, class II medical device. Fourth Frontier will partner with Independent Diagnostic Testing Facilities (IDTFs) and cardiac rehabilitation centres to offer at-home remote monitoring services.

» Subscribe to AW magazine here, check out our new podcast here or sign up to our digital archive of back issues from 1945 to the present day here

The post Revolutionising heart health: Frontier X Plus gains FDA clearance appeared first on AW.

[ad_2]

Source link